What you see here is JARG's first blog. The idea behind this page is to inform our readers of relevant behind-the scene facts and events, which usually are not widely (or at all) covered in medical journals. The idea is to be informative and, at times, a little irreverent. To do this well, we also count on you, our readers, for information. If you believe to have relevant information, which may be of interest to other readers of JARG, please e-mail us at editorial@thechr.com.
If your contribution is accepted, it may be edited before publication. We offer a guarantee of confidentiality to all contributors who wish to remain "off the record." All others will be given full credit for their contribution.
JARG news
What's good for the goose is also good for the gender. What better way to start this page, therefore, than to reveal some behind the scenes events at JARG, itself: After quite lengthy negotiations, Norbert Gleicher, M.D. finally renewed his contract as Editor-in-Chief with Springer, the new Publisher of this Journal. The interesting, little secret is that this renewal almost didn't happen. Indeed, Gleicher had already submitted his resignation, but reconsidered after Springer, belated, agreed to implement a number of long overdue changes at the Journal. The Journal will, therefore, amongst other editorial changes, in the very near future present itself with a new two color lay out, greatly improving the visual appearance of its printed pages. Changes have also taken place on the Editorial Board: In an attempt to attract new ideas and bring an improved energy level to JARG, the Publisher and Gleicher have initiated the most radical remake of the Board since the inception of the Journal. In a first meeting of the new Board during the Annual ASRM Meeting in New Orleans, a variety of new projects were discussed for the Journal, many of which will be implemented over the coming publication year.
Comings and goings
After a long, and distinguished, cadence, Joe Leigh Simpson, M.D. has resigned a Chairman of the Department of Ob/Gyn at Baylor College of Medicine in Houston, Texas. Simpson, by many considered the "Father of Genetics" in Obstetrics and Gynecology, and also a long-standing member of this Journal's Editorial Board, announced his resignation, however, under somewhat unusual circumstances. What we have heard through the grapevine is that, one day, Baylor's administration simply decided to sell part of Simpson's department to another, close by, hospital. Simpson, not surprisingly, wasn't very enthusiastic about this idea but, as has become common practice amongst medical school and hospital administrations, nobody really cared what their distinguished department chair really thought. JARG Blog was unable to confirm details with Simpson, or his wife Sandra Carson, M.D., also a professor in the department and head of its IVF-unit, but what we heard was that things got even more interesting when the IVF-unit suddenly was evicted from its premises at the hospital. Being an academic department Chair has become a truly dangerous profession.
ASRM 2006, New Orleans
Held in New Orleans, as one of the first major gatherings in this city after Hurricane Katrina, this year's Annual ASRM Meeting appeared somewhat out of the ordinary. And it was not only the relatively somber mood in the historically very upbeat metropolis that appeared different. Even though attendance numbers at the meeting were quoted as good, individual events appeared smaller than usual: The size of the exhibition hall appeared dramatically shrunk in comparison to preceding years, clearly reflecting a down sizing in industry support for the meeting (and maybe the specialty?). Roundtable luncheons, traditionally oversubscribed, demonstrated gaping absences at practically all tables. Industry also appeared stingy in support of the traditional evening events, whether as a reflection of a shrinking infertility market, (see the October issue of Fertility and Sterility) or in consideration of new Pharma Guidelines, which greatly restrict what the pharma industry is now allowed to offer as physician support. Whichever the cause, all in all, New Orleans did not reflect the usual experience Annual ASRM Meetings traditionally have conveyed, and one wonders whether this was only the reflection of a still beaten down New Orleans or, maybe, of a medical specialty area in need of new ideas in order to resume growth.
Pharma: The Serono and Organon Stories
An era in our specialty has clearly come to a close with the announcement, on September 21, 2006, that Merck KGaA, of Darmstadt, Germany (not to be mixed up with the U.S. pharma company of the same name), had acquired Serono. Love the company, or hate it, everybody in reproductive medicine has grown up with Serono. An iconic entity in the field since a prior generation of owners had build a tiny Italian company into a world-wide pharma giant, at least initially based on principally only one product,-urinary human menopausal gonadotropin. When the company in the 1980's effected a switch from urinary to recombinant gonadotropins, many felt that this not only reflected a technological milestone for Serono, which, by doing so, transformed itself into a leading world-wide biotech company, but it somehow, also changed the closeness this company had achieved with a world-wide community of fertility providers, who, suddenly, no longer felt they were close family, but, at best, distant relatives. As Serono successfully developed pharmaceutical products for non-fertility-related areas in medicine, the company's core interests moved away from reproductive medicine. A second, Harvard Business School-trained, generation of the Bertarelli family really never succeeded (or never wanted to succeed) in reestablishing closeness with the community of practitioners. Especially within the U.S., this led to an almost incredible loss of market share to competitors, like Organon and Ferring. It may, therefore, after all, not be so bad that the company was sold. Maybe, it is time for a new beginning. We have heard through the grapevine that considerable changes are in store from the top down. Our last information was that the name for the company, most likely, will not remain the same but has not yet been finally determined. Expect a combination of Merck and Serono in the new company identity. An era is over! The emperor is dead. Long live the new one! Corporate upheaval is not only restricted to Serono. Possibly as a reflection of world wide shrinkage of the fertility market, significant changes are also reported by Organon, historically a part of the multinational giant Akzo Nobel. Now it appears that the mother ship no longer wishes to be affiliated with its pharma business and is planning to split it into a completely separate company, to be called Organon Biosciences (its core business of coatings and chemicals will remain under the old corporate name). This will apparently happen in steps, with a first being a minority divestment and full separation expected within two to three years. In the meantime, the provider community awaits the changes, which always follow such corporate restructuring. We, therefore, can expect during 2007 major revamps at the two largest pharmaceutical suppliers to our specialty. As the Chinese usually wish their enemies: may you live in interesting times! One just wonders, what gives us this honor?
